
    
      This is a pharmacogenomic phase II, multicenter, prospective clinical trial whose main
      objective is to evaluate the association of molecular and imaging markers with the response
      to bevacizumab administration in combination with docetaxel and doxorubicin as neoadjuvant
      chemotherapy in patients diagnose with locally advanced breast cancer.
    
  